期刊文献+

多巴胺转运蛋白显像剂^(18)F-FP-CIT脑PET显像评价脑内多巴胺能系统功能 被引量:4

Assessing brain dopamine system by dopamine transporter ligand ^(18)F-FP-CIT with positron emission tomography
在线阅读 下载PDF
导出
摘要 目的 本研究应用放射性显像剂18F FP CIT进行脑PET显像来评价脑内的DA能系统的功能变化 ,并从安全性、有效性等方面对本方法进行评价。方法 分别对猴、正常人和不同程度的帕金森病患者应用18F FP CIT进行脑PET显像 ,观察其安全性和在不同程度PD患者的图像表现。结果 正常猴 1h断层图像上脑内双侧尾状核和壳核出现较高的放射性浓聚 ;3h双侧纹状体放射性相对更为浓聚。正常人 15min和 3 0min脑断层图像上双侧尾状核和壳核出现放射性摄取 ,同时大脑皮层有一定程度的放射性摄取 ,2h图像已非常清晰 ,仅尾状核和壳核清晰可见。 5 7例PD患者PET图像中 ,PD患者症状与对侧脑后壳核放射性的降低明显相关。结论 DAT显像可从分子水平评价多巴胺递质系统功能的客观情况 。 Objective To evaluate the usefulness of dopamine transporters (DAT) imaging in diagnosing Parkinson's disease by PET scan, and to assess the method by observing the security and its validity. Methods 18 F-FP-CIT PET was studied in 2 monkeys, 4 healthy controls, 21 parkinsonian patients with early stage and 36 parkinsonian patients with advanced stage. Results DAT uptake could be observed in bilateral caudate and putamen of monkey 1 hour after injection, the better image was seen at 3 hour.In the normal control, image shows the uptake of DAT in bilateral caudate and putamen and brain cortex at 15 min and 30 min after injection. Only caudate and putamen could be seen in the 2 hour image. In the 57 patients with Parkinson's disease, the binding uptake in contralateral caudate, anterior and posterior putamen was significantly reduced, the DAT binding uptake in contralateral posterior putamen is correlated with symptoms of PD patients. Conclusion 18 F-FP-CIT PET can evaluate the Parkinson's disease at the molecular level.DAT PET is an important clinical molecular imaging tool.
出处 《中国医学影像技术》 CSCD 2004年第9期1421-1424,共4页 Chinese Journal of Medical Imaging Technology
基金 国家科学技术部"十五"国家科技攻关课题(2 0 0 1BA70 2B0 2 )
关键词 正电子发射计算机断层摄影 帕金森病 ^18F-FP-CIT Positron emission tomography Parkinson's disease 18 F-FP-CIT
  • 相关文献

参考文献4

  • 1Chaly T, Dhawan V, Kazumata K, et al. Radiosynthesis of [18F]N-3-fluoropropyl-2-β-carbomethoxy-3-β-(4-iodophenyl)nortropane and the first human study with positron emission tomography[J]. Nucl Med & Bio, 1996, 23(8): 999-1004.
  • 2Rinne J, Ruottinen H, Bergman J, et al. Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease[J]. J Neurol Neurosurg Psychiatry, 1999, 67(6):737-741.
  • 3Nurmi E, Ruottinen H, Kaasinen V, et al. Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F] CFT[J]. Ann Neurol, 2000, 47(6):804-808.
  • 4Kazumata K, Dhawan V, Chaly T, et al. Dopamine transporter imaging with fluorine-18-FPCIT and PET[J]. J Nucl Med, 1998, 39(9):1521-1530.

同被引文献34

引证文献4

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部